2006
An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens
Wang B, He J, Liu C, Chang L. An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 2006, 24: 3477-3489. PMID: 16530303, PMCID: PMC1850619, DOI: 10.1016/j.vaccine.2006.02.025.Peer-Reviewed Original ResearchConceptsTumor-associated antigensDendritic cellsModification of DCsMultiple tumor-associated antigensStrong anti-tumor responsesReactive dendritic cellsAnti-tumor responseT cell responsesLentiviral vectorsCancer-specific antigensCell antigen 2Tumor-bearing miceThymidine kinase suicide geneDC vaccinesVaccine modalitiesCancer immunotherapyCancer patientsTherapeutic injectionsTherapeutic effectExtended survivalAntigen 2Danger signalsVivo eliminationCell responsesTherapeutic potential
2002
Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
Teshima T, Liu C, Lowler K, Dranoff G, Ferrara J. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Research 2002, 62: 796-800. PMID: 11830535.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationBone marrow transplantationDonor leukocyte infusionImmunization of donorsLeukocyte infusionMarrow transplantationTumor vaccinesT cellsT cell-depleted allogeneic bone marrow transplantationTumor-specific T-cell responsesTumor vaccine efficacyDonor T cellsRecurrence of malignancyPotent antitumor immunityT cell responsesAnalysis of splenocytesT cell proliferationGranulocyte-macrophage colony-stimulating factorPotent T-cell proliferationNovel treatment strategiesColony-stimulating factorSpecific antitumor activityB16 melanoma cellsBeneficial graftHarmful graft